We previously demonstrated that inhibiting the MEK-ERK pathway with a MEK inhibitor, in combination with a PPARγ agonist, facilitates the differentiation of breast cancer cells into adipocytes [6,9]. Here, MAP2K7 is linked to breast carcinoma.